Axogen, Inc.

What they do

Axogen develops and sells products for peripheral nerve regeneration and repair, primarily to surgeons at Level 1 trauma centers and academic-affiliated hospitals. Its portfolio includes the Avance Products (Avance, an FDA-approved acellular nerve scaffold approved December 3, 2025, and Avance Nerve Graft, a processed human nerve allograft), Axoguard Nerve Connector, Protector, HA+ Protector and Cap, and Avive+ Soft Tissue Matrix. Products are available in the U.S., Canada, Germany, the U.K., Spain and several other countries, but the company derives substantially all revenue from U.S. sales.

Revenue drivers

• Avance Products (Avance and Avance Nerve Graft) — Nerve allografts used to bridge severed peripheral nerves. The 10-K risk factors state approximately 60% of total revenues come from Avance Products, making this the single largest revenue line.
• Axoguard portfolio (Nerve Connector, Protector, HA+ Protector, Nerve Cap) — Porcine submucosa ECM products for tensionless repair, nerve protection, and neuroma management, sold alongside Avance in nerve repair procedures.
• Avive+ Soft Tissue Matrix — Multi-layer amniotic membrane allograft launched June 24, 2024, regulated as a Section 361 HCT/P, used to protect and separate tissues in the surgical bed.
• Procedure markets: Extremities, Oral Maxillofacial & Head and Neck, Breast — Q2 2026 year-to-date growth was broad-based across these three markets, driven by 20%+ account productivity and expanding sales force coverage; Breast growth was greater than 50% year over year.

Recent performance

Q2 2026 revenue was $69.7 million, up 23.1% from $56.7 million in Q2 2025. Gross margin was 72.7% versus 74.2%, which the company attributed to product mix, primarily accelerating Breast growth greater than 50%. Q2 2026 net loss was $1.5 million, or $0.03 per share, compared with net income of $0.6 million, or $0.01 per share, a year earlier; adjusted net income was $7.3 million, or $0.12 per share, and adjusted EBITDA was $8.4 million versus $9.3 million. Full-year 2025 revenue was $225.2 million, up 20.2%, with a net loss of $15.7 million, or $0.34 per share. Cash, restricted cash and investments were $113.4 million at June 30, 2026, up $9.8 million from March 31, 2026.

Strategy

Management states its strategy is to deepen presence in high-potential accounts, specifically Level 1 trauma centers and academic-affiliated hospitals with a high number of trained microsurgeons, and to expand nerve repair indications and adoption of its nerve repair algorithm across multiple surgical specialties. The company is investing in clinical evidence, including the published REPOSE randomized study of Axoguard Nerve Cap and the initiated Nerve-RESTORE randomized study comparing Avance Nerve Graft to sural nerve autograft. It acquired a minority ownership stake in Trace Biosciences, with a limited right of first refusal, to support nerve-specific imaging technology. Coverage and reimbursement expansion continues: 2025 new lives covered reached approximately 19.8 million, commercial payer coverage exceeded 65%, and a new CMS Level 3 Nerve Procedure Code effective January 1, 2026 raised Avance facility reimbursement.

Risks

• Avance concentration — Approximately 60% of total revenues come from Avance Products, so any adverse FDA action, narrowed indication, or commercialization limitation for Avance would materially reduce revenues.
• Accelerated approval confirmatory studies — Portions of Avance's approved indication were granted under accelerated approval, and continued approval depends on timely completion of post-marketing confirmatory studies; failure to verify clinical benefit could result in withdrawal or restriction.
• Regulatory status of Avive+ Soft Tissue Matrix — Avive+ is regulated solely under Section 361 of the PHS Act as an HCT/P, a category the 10-K describes as under close FDA scrutiny and potentially subject to regulatory change.
• Macroeconomic and trade disruption — The 10-Q cites financial market volatility, geopolitical tensions and escalating trade disputes; while direct tariff exposure is limited, broader trade-war-driven instability could cause net revenue to fluctuate.

Outlook

For 2026, management guides to full-year revenue growth of at least 24%, or revenue of at least $279 million, gross margin of at least 73%, and positive free cash flow. This guidance follows the Q2 2026 print of $69.7 million in revenue and $113.4 million in cash, restricted cash and investments. The company also points to the January 23, 2026 public offering that raised $133.3 million, which supports its stated priorities.